Inovio Pharmaceuticals Inc (INO : NASDAQ)
Common Stock
$1.15
USD
+0.00 (%)
Last updated: 2026-09-17
Get INO alerts:
INO
Inovio Pharmaceuticals Inc
WealthAwesomePerformance
1 Day
-0.86%
1 Week
-12.88%
1 Month
+0.00%
YTD
+3.60%
Key Statistics
Market Cap
$118.91M
52W High
$2.72
52W Low
$0.56
P/E Ratio
-
50 Day MA
$1.09
200 Day MA
$1.41
Beta
1.63
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $1.15 | $1.25 | $1.15 | $1.21 | $1.21 | 2,719,531 |
| 9/16/2026 | $1.18 | $1.18 | $1.08 | $1.15 | $1.15 | 3,367,600 |
| 9/15/2026 | $1.20 | $1.20 | $1.14 | $1.16 | $1.16 | 2,641,900 |
| 9/14/2026 | $1.24 | $1.26 | $1.16 | $1.18 | $1.18 | 3,276,100 |
| 9/11/2026 | $1.30 | $1.31 | $1.23 | $1.25 | $1.25 | 2,388,400 |
| 9/10/2026 | $1.34 | $1.34 | $1.28 | $1.28 | $1.28 | 1,949,500 |
| 9/9/2026 | $1.41 | $1.45 | $1.32 | $1.32 | $1.32 | 2,685,100 |
| 9/8/2026 | $1.43 | $1.45 | $1.38 | $1.42 | $1.42 | 3,471,500 |
| 9/4/2026 | $1.35 | $1.43 | $1.35 | $1.43 | $1.43 | 2,910,100 |
| 9/3/2026 | $1.37 | $1.44 | $1.33 | $1.36 | $1.36 | 4,198,500 |
Analyst Price Targets
Based on 5 analysts covering INO · as of Sep 17, 2026
Wall Street analysts forecast INO stock price to rise 175.4% over the next 12 months.
Consensus
Buy4.00 / 5.00
Avg. Target
US$3.17
+175.4% Upside
Current Price
US$1.15
Last close
Analyst Breakdown (5 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on INO's historical volatility
30-Day Vol
94.6%
Annualized
90-Day Vol
119.8%
Annualized
Trend (90d)
+28.7%
Annualized drift
90d Mean
US$1.34
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$1.25 | US$0.90 – US$1.74 |
| 60 trading days | US$1.30 | US$0.82 – US$2.06 |
| 90 trading days | US$1.34 | US$0.76 – US$2.36 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-77.93M
- Profit Margin
- 0.00%
- ROE (TTM)
- -409.87%
- EPS (Diluted)
- -1.03
- Book Value
- 0.05
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About INO.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |